Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Mats O, Magnusson"'
Publikováno v:
The Journal of Clinical Pharmacology. 63:435-444
Systemic lupus erythematosus (SLE) is a systemic, autoimmune disease characterized by chronic inflammation and organ damage. Dapirolizumab pegol inhibits CD40 ligand (CD40L) and is currently undergoing phase 3 trials for the treatment of SLE. To desc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c37d05bab569412d18975ee0a4982ea
https://doi.org/10.1002/jcph.2188
https://doi.org/10.1002/jcph.2188
Autor:
Fei Tang, Jurgen Langenhorst, Steve Dang, Nastya Kassir, Ryan Owen, Barbara Purdon, Mats O. Magnusson, Rong Deng
Publikováno v:
The Journal of Clinical Pharmacology. 63:197-209
The pharmacokinetics (PK) of tenecteplase in patients with acute ischemic stroke has not been extensively studied. This study aimed to describe PK characteristics of tenecteplase in patients with acute myocardial infarction (AMI) using a population P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::529d7bb05b39040e68555b1170ba2b62
https://doi.org/10.1002/jcph.2164
https://doi.org/10.1002/jcph.2164
Autor:
Mats O. Magnusson, A Ør Knudsen, Beyhan Ataseven, I Braicu, D Berton, Hannelore Denys, Kristina Lindemann, Pierre-Etienne Heudel, S Altintas, R. dePont Christensen, Johanna Mäenpää, M Mirza, Ignace Vergote, Caroline Lundgren, Anne Floquet, Frédéric Selle, Jalid Sehouli, Philippe Follana, Michel Fabbro, Jens Huober
Publikováno v:
Late breaking abstracts.
Introduction/Background* Endometrial cancer (EC) patients (Pts) with advanced and recurrent disease relapse despite treatment with combination chemotherapy and have a short progression-free survival (PFS). Nintedanib (N) is a potent, orally available
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8de9df7cb5dab08fcbd632990a24a136
https://doi.org/10.1136/ijgc-2021-esgo.656
https://doi.org/10.1136/ijgc-2021-esgo.656
Autor:
Annika Auranen, Kenneth Grønkjær Madsen, JR Henriksen, M Waldstroem, R. dePont Christensen, Mats O. Magnusson, L Tandaric, Kristina Lindemann, S Lindberg, Line Bjørge, Johanna Mäenpää, Henrik Roed, L Akslen, M Mirza
Publikováno v:
Late breaking abstracts.
Introduction/Background* The primary objective of this multicentre, phase II study was to evaluate the preliminary efficacy of O (3000mg, IV q2W) in combination with D (1500mg, IV, q4W) in relapsed OC patients with the CD73 expression on intraepithel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::683f839cff3f9cc00ee1e89c2fe30aa6
https://doi.org/10.1136/ijgc-2021-esgo.668
https://doi.org/10.1136/ijgc-2021-esgo.668
Publikováno v:
Acta radiologica (Stockholm, Sweden : 1987). 63(5)
Background Iodine quantification using dual-energy computed tomography (DECT) is helpful in characterizing, and follow-up after treatment of tumors. Some malignant masses, for instance papillary renal cell carcinomas (p-RCC), are hard to differentiat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc8f9131c48431835bbfc695a54ff3f6
https://pubmed.ncbi.nlm.nih.gov/33887965
https://pubmed.ncbi.nlm.nih.gov/33887965
Autor:
Mats O. Magnusson, Monica Segelsjö, Anders Magnusson, Adina Ljungberg, Pär Dahlman, Malin Helenius
Introduction The protocol for preparation of computed tomography urography (CTU) examinations at our hospital was changed in 2013 to improve the quality of urinary bladder filling in the excretory phase. The aim of this study was to evaluate the qual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1de00e46823371b3c3a35269ef45970b
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-417331
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-417331
Publikováno v:
Respiratory medicine. 180
Background The tyrosine kinase inhibitor nintedanib reduces the rate of decline in forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF), other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7456c74edf88971eeee978b574e97606
https://pubmed.ncbi.nlm.nih.gov/33798871
https://pubmed.ncbi.nlm.nih.gov/33798871
Autor:
E. Niclas Jonsson, Christian Hove Rasmussen, Paula Burger, Mike K. Smith, Luke Fostvedt, Lynn McFadyen, Vijayakumar Sundararajan, Mats O. Magnusson, Timothy Nicholas, Thomas G. Tensfeldt, Kaori Ito
Publikováno v:
The AAPS journal. 20(3)
Every year, the pharmaceutical industry generates a large number of scientific reports related to drug research, development, and regulatory submissions. Many of these reports are created using text processing tools such as Microsoft Word. Given the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fe726174d29dc4d74e4b6284340a1e7
https://pubmed.ncbi.nlm.nih.gov/29549459
https://pubmed.ncbi.nlm.nih.gov/29549459
Autor:
Stefaan Rossenu, Mats O. Magnusson, An Vermeulen, Elodie L. Plan, Alberto Russu, E. Niclas Jonsson, Mahesh N. Samtani
Publikováno v:
CNS drugs. 31(4)
Paliperidone palmitate 3-month formulation (PP3M), a long-acting injectable atypical antipsychotic, was recently approved in the US and Europe for the treatment of schizophrenia in adult patients who have already been treated with paliperidone palmit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da5f63422101ff2b9f3e5e562929cd49
https://pubmed.ncbi.nlm.nih.gov/28258365
https://pubmed.ncbi.nlm.nih.gov/28258365
Autor:
Alberto Russu, E. Niclas Jonsson, Stefaan Rossenu, Elodie L. Plan, An Vermeulen, Mats O. Magnusson, Mahesh N. Samtani
Publikováno v:
Clinical pharmacokinetics. 56(4)
Our objective was to characterize the population pharmacokinetics of paliperidone after intramuscular administration of its long-acting 3-month formulation palmitate ester at various doses and at different injection sites (deltoid and gluteal muscles
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb034d5fca0cff97225a8fef50b830f3
https://pubmed.ncbi.nlm.nih.gov/27743205
https://pubmed.ncbi.nlm.nih.gov/27743205